Innovation Pharmaceuticals Inc (IPIX)

[loanranger]

"His remarks were that we may not get that one because it’s having safety issues in the trials because it’s damaging the liver and failing enzyme tests."


From the Phase 1 study by Polymedix on PMX-30063. (Brilacidin)
"As seen in previous Phase 1 clinical studies, there were a few minor and transient increases in liver enzymes that were not clinically significant. All subjects demonstrated complete return to normal clinical parameters and reported no adverse effects by the time of the last follow up visit."
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=109750003&txt2find=enzymes

After the Phase 2:
"All Brilacidin treatment regimens were well tolerated. There were six severe adverse events (SAE) reported across the study, none of which were considered related to Brilacidin by the principal investigator."
http://www.ipharminc.com/press-release/2016/11/16/cellceutix-announces-positive-top-line-data-from-phase-2b-absssi-trial-single-dose-brilacidin-comparable-to-7-days-of-daptomycin
If the Company reported issues with liver enzymes in the Phase 2 tests that weren't considered serious adverse events I didn't see them.


Ask your Dr. where he gets his info.